Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegipanermin - INmune Bio

Next Previous
Drug Profile

Pegipanermin - INmune Bio

Alternative Names: DN-TNF; INB-03; LIVNate™; Quellor™; Soluble tumour necrosis factor inhibitor; XENP1595; XENP345; XPro 1595; XPro595; XProTM

Latest Information Update: 16 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emory University; Xencor
  • Developer Alzheimer's Association; Emory University; FPRT Bio; INmune Bio; Xencor
  • Class Anti-inflammatories; Antidementias; Antidepressants; Antineoplastics; Antiparkinsonians; Hepatoprotectants; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Immunostimulants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Major depressive disorder; Mild cognitive impairment
  • Preclinical HER2 positive breast cancer
  • No development reported Neurodegenerative disorders; Non-alcoholic steatohepatitis; Solid tumours
  • Discontinued COVID-19 respiratory infection; Parkinson's disease

Most Recent Events

  • 08 May 2025 INmune Bio plans a phase II trial for Major depressive disorder (Treatment-resistant) once NIH funding is available
  • 30 Sep 2024 INmune Bio completes enrolment in its phase II trial for Alzheimer's disease (In the elderly) in US, Germany, Poland, the Czech Republic, Slovakia, Australia, United Kingdom, Spain, France, and Canada (NCT05318976)
  • 24 Sep 2024 Efficacy data from the phase II trial in Alzheimer's disease released by INmune Bio

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top